RecruitingPhase 2NCT06074692

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Principal Investigator
Weibin Zhang, PhD, MD
Ruijin Hospital
Intervention
Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)(combination_product)
Enrollment
86 target
Eligibility
10-70 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06074692 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma →

← Back to all trials